NOAH Compendium

Printed from NOAH Compendium (https://www.noahcompendium.co.uk). (c) Copyright NOAH Compendium 2024. All Rights Reserved.
Date: Friday, November 8, 2024 8:18

Release 2.60
Cazitel 230/20 mg Flavoured Film-Coated Tablets for Cats
 
Species: Cats
Therapeutic indication: Pharmaceuticals: Endoparasiticides: Anthelmintics for cats
Active ingredient: Praziquantel, Pyrantel Embonate
Product:Cazitel® Flavoured Tablets for Cats
Product index: Cazitel Flavoured Tablets for Cat
Incorporating:
Presentation
A white to off-white round, biconvex coated tablet with a breakline on one side containing 230 mg pyrantel embonate (equivalent to 79.79 mg pyrantel) and 20 mg praziquantel.
Uses
Indicated for the treatment of mixed infections caused by the following gastrointestinal roundworms and tapeworms in cats:
Roundworms: Toxocara cati, Toxascaris leonina
Tapeworms: Dipylidium caninum, Taenia taeniaeformis, Echinococcus multilocularis.
Dosage and administration
Oral use.
The recommended dose is 20 mg/kg bodyweight pyrantel (equivalent to 57.5 mg/kg pyrantel embonate) and 5 mg/kg praziquantel. This is equivalent to 1 tablet per 4 kg bodyweight.
The tablets should be given directly to the cat but if necessary can be disguised in food.
To ensure a correct dosage, bodyweight should be determined as accurately as possible.
Dosage table (guide):
Bodyweight (kg)
Tablets
1.0 - 2.0
½
2.1 - 4.0
1
4.1 - 6.0
1 ½
6.1 - 8.0
2
In ascarid infestation, especially in kittens, complete elimination cannot be expected, so a risk of infection for humans can persist. Repeat treatments should therefore be carried out with a suitable roundworm product at 14 day intervals until 2-3 weeks after weaning. If signs of disease persist or appear, consult a veterinary surgeon.
Contra-indications, warnings, etc
Do not use simultaneously with piperazine compounds.
Do not use in kittens less than 6 weeks of age.
Do not use in cases of hypersensitivity to the active substances or to any of the excipients.
Do not use during pregnancy but may be used during lactation.
As the tablets are flavoured, they should be stored in a safe place out of the reach of animals.
Animals in a poor condition or heavily infested, which can be manifested by symptoms such as diarrhoea, vomiting, presence of parasites in faeces and vomit, poor hair condition, should be examined by a veterinarian prior to the product administration. For severely debilitated or heavily infested cats, use only according to a benefit/risk assessment by the responsible veterinarian.
Very rare
(<1 animal / 10,000 animals treated, including isolated reports)
Digestive tract disorder (vomiting and/or hypersalivation)
Neurological signs (eg ataxia and muscle tremor)
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system.
Fleas serve as intermediate hosts for one common type of tapeworm Dipylidium caninum. Tapeworm infestation is certain to reoccur unless control of intermediate hosts such as fleas, mice, etc. is undertaken.
If there is a risk for re-infestation, the advice of a veterinarian should be sought regarding the need for and the frequency of repeat administration in cats. Local epidemiological information and the living conditions of the cat should be taken into account. It is also important to remove sources of possible re-infection such as fleas and mice.
Parasite resistance to any particular class of anthelmintic may develop following frequent, repeated use of an anthelmintic of that class.
After doses higher than 5 times the recommended dose, signs of intolerance such as vomiting have been observed.
User warnings
In case of accidental ingestion, seek medical advice and show the package leaflet or the label to the physician.
In the interests of good hygiene, persons administering the tablets directly to the cat, or by adding them to the cat’s food, should wash their hands afterwards.
Echinococcosis represents a hazard for humans. As echinococcosis is a notifiable disease to the World Organisation for Animal Health (OIE), specific guidelines on the treatment and follow-up, and on the safeguard of persons, need to be obtained from the relevant competent authority.
Pharmaceutical precautions
This veterinary medicinal product does not require any special storage conditions.
Medicines should not be disposed of via wastewater. Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
Unused half tablets must be discarded.
Keep out of the sight and reach of children.
For animal treatment only.
Legal category
Legal category: NFA-VPS
Packaging quantities
Cartons containing 24 tablets.
Further information
None.
Marketing Authorisation Holder (if different from distributor)
Chanelle Pharmaceuticals Manufacturing Ltd.
Marketing Authorisation Number
UK(GB): Vm 08749/5044
UK(NI): Vm 08749/3008
Significant changes
GTIN
GTIN description:24 tablets
GTIN:05013457080223